HAZLET, N.J. - s4story -- This program is specifically designed for the liver/GI specialty audience: hepatologists, gastroenterologists, and advanced practice providers who manage patients with MASH and are positioned to implement the updated NIT framework, initiate approved pharmacotherapy, and counsel patients on emerging options.

Click here for more information

CHAIR
Arun Sanyal, MD
Chief, Division of Gastroenterology, Hepatology, and Nutrition
Professor of Medicine, Physiology and Molecular Pathology
Virginia Commonwealth University School of Medicine
Richmond, Virginia

FACULTY
Rohit Loomba, MD, MHSc
Chief, Division of Gastroenterology and Hepatology
Director, UC San Diego MASLD Research Center
Professor of Medicine
UC San Diego Health
San Diego, California

Mazen Noureddin, MD, MHSc
Professor of Medicine
Sherry and Alan Conover Center for Liver Disease & Transplantation

More on S For Story

• Hunter Is Releasing New Music For The Holidays!
• Tixpool.com - Naija Premier Event Reseller
• Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
• The First UNOFFICIAL Minecraft Graphic Novel by Marlon Birch
• Briarhaven Publishing Releases Softly Breathe

Underwood Center for Digestive Health
J.C. Walter Jr. Transplant Center
Houston Methodist
Houston, Texas

Mary Rinella, MD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
The University of Chicago Medicine
Chicago, Illinois

Educational Objectives

• Apply the AASLD-endorsed stepwise non-invasive testing framework — including FIB-4, VCTE/ELF, and MRE — to identify patients with MASH and significant fibrosis (F2–F3) who are candidates for pharmacotherapy, and describe the role of liver biopsy in cases of diagnostic uncertainty
• Compare the mechanism of action, Phase 3 clinical evidence, patient selection criteria, and monitoring requirements for resmetirom and semaglutide 2.4 mg/week in patients with non-cirrhotic MASH and F2–F3 fibrosis, and apply this comparison to individualized treatment decisions based on patient comorbidity profile
• Characterize the FGF21 analog class — including efruxifermin and pegozafermin — by mechanism of action, Phase 2 and Phase 3 evidence to date, and current regulatory status, and describe the evidence supporting the investigational role of FGF21 analogs in patients with pre-cirrhotic MASH and compensated cirrhosis due to MASH
• Formulate an evidence-based management plan for patients with compensated MASH cirrhosis, including surveillance priorities, appropriate use of approved therapies for comorbid conditions, and accurate patient communication regarding investigational treatment options

Target Audience
This program is targeted to hepatologists and gastroenterologists and other advanced practice providers practicing in hepatology and gastroenterology.

More on S For Story

• You Are Already Changing the World: How Personal Healing Sparks Collective Change
• Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
• New Children's Book 'The Grief Well' Helps Kids Understand Grief, Loss, Memories, and Love
• Award-Winning Author Malcolm Havard Releases New Historical Thriller - The Adler Legacy
• Award-Winning LIVE IT! Celebrates Collaborative Success as Creator Jodi Hope Grinwald Announces Next

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA
Category Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a
certificate of completion as AANP accepts AMA PRA Category 1 Credits™
through its reciprocity agreements. The National Commission on Certification
of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.